Abstract: A reactive mass label for labelling a biological molecule for detection by mass spectrometry, which label comprises a reactive functionality for labelling thiol groups or carbonyl groups. Also provided is a reactive mass label for labelling a biological molecule for detection by mass spectrometry, wherein the mass label comprises the following structure: X-L-M-S-Re wherein X is a mass marker moiety, L is a cleavable linker, M is a mass normalization moiety, S is a mass series modifying group comprising the following group: wherein J is C?O, K is NH, and n is 2 or J and K are both CH2 and n is 1, and wherein m is at least 1; and Re is a reactive functionality for attaching the mass label to a biological molecule.

Abstract: A cartridge (1) is provided comprising a cartridge case (2) and a projectile arrangement (3; 3?) with an arrow projectile (5; 5?) with a sub-caliber control unit (7), wherein the projectile arrangement (3; 3?) is connected to the cartridge case (2) via a case cover (4), wherein, after firing of the projectile arrangement (3; 3?), a precise guiding of the arrow projectile (5; 5?) in the corresponding weapon barrel is ensured due to a receptacle device (28; 28?) that centers the control unit (7) of the arrow projectile (5; 5?), and that can be separated from the control unit (7) when the projectile arrangement (3; 3?) is fired. The receptacle device is connected to the case cover (4) on the projectile side, wherein the receptacle device grasps a ring-shaped rear flange (29; 29?) whose outer diameter corresponds to the projectile caliber of the respective cartridge (1).

Abstract: The invention relates to producing a propellant charge igniter tube (2) for a propellant charge igniter (1) by means of hydroforming (high-pressure forming). According to the present invention, a sleeve base (6) is then joined to the propellant charge igniter tube (2) by means of friction welding, for example, and vulcanized without reworking. In this context, the rubber lips of the sleeve base (6) and the propellant charge igniter tube (2) are molded on, or vulcanized, on in one operation. The vacuum-packed benites (8) and the lower part (9) of the propellant charge igniter (1) can then be mounted in the sleeve base (6).

Abstract: Methods and compositions relating to Alzheimer's disease are provided. Specifically, proteins that are differentially expressed in the Alzheimer's disease state relative to their expression in the normal state are provided. Proteins associated with Alzheimer's disease are identified and described. Methods of diagnosis of Alzheimer's disease using the differentially expressed proteins are also provided, as are methods for the identification and therapeutic use of compounds for the prevention and treatment of Alzheimer's disease.

Abstract: The disclosure provides a method for assaying for a target analyte, comprising providing a plurality of samples which may comprise the target analyte, wherein each sample is differentially labelled with a mass label or a combination of mass labels, wherein the mass labels are from a set of mass labels, wherein each mass label is an isobaric mass label comprising a mass spectrometrically distinct mass marker group, such that the samples can be distinguished by mass spectrometry and determining from the mass spectrum the quantity of the target analyte in each sample.

Abstract: Methods and compositions relating to Alzheimer's disease are provided. Specifically, proteins that are differentially expressed in the Alzheimer's disease state relative to their expression in the normal state are provided. Proteins associated with Alzheimer's disease are identified and described. Methods of diagnosis of Alzheimer's disease using the differentially expressed proteins are also provided, as are methods for the identification and therapeutic use of compounds for the prevention and treatment of Alzheimer's disease.

Abstract: A projectile (1) is optionally used as a fragmentation projectile or as a projectile that utilizes a pressure wave effect created when the explosive charge (3) explodes. The projectile (1) contains an ejection charge (12), and an explosive charge (3) arranged in a jacket (4) that can be moved axially with respect to a fragmentation casing (5). The ejection charge (12) allows the explosive charge (3) and surrounding jacket (4) to be pushed at least so far out of the projectile casing (2) that, in the event of explosion, the explosive charge does not act on the fragmentation casing (5). In order to ensure that the jacket (4) of the explosive charge (3) does not develop any fragmentation effect, or develops only a small fragmentation effect, when the explosive charge (3) is ignited, a molded part composed of plastic or a light alloy is used as the jacket (4).

Abstract: A cartridge (1) is provided comprising a cartridge case (2) and a projectile arrangement (3; 3?) with an arrow projectile (5; 5?) with a sub-caliber control unit (7), wherein the projectile arrangement (3; 3?) is connected to the cartridge case (2) via a case cover (4), wherein, after firing of the projectile arrangement (3; 3?), a precise guiding of the arrow projectile (5; 5?) in the corresponding weapon barrel is ensured due to a receptacle device (28; 28?) that centers the control unit (7) of the arrow projectile (5; 5?), and that can be separated from the control unit (7) when the projectile arrangement (3; 3?) is fired. The receptacle device is connected to the case cover (4) on the projectile side, wherein the receptacle device grasps a ring-shaped rear flange (29; 29?) whose outer diameter corresponds to the projectile caliber of the respective cartridge (1).

Abstract: The invention relates to a projectile (1) having a sub-caliber projectile core (2) and a guide cage or sabot (3) that comprises a driving element (4), which acts on the projectile core (2) at the rear thereof and is in the form of a plate composed of metal. In order to produce such a projectile (1) at low cost, the projectile core (2) and the driving element (4), which is in the form of a plate, are inserted as inserts into an injection-molding tool, and are extrusion-coated so that the injection-mold shape is chosen so that the contour of the guide cage or sabot (3) of the projectile (1) is produced after the injection-molding process.

Abstract: A projectile in which the metallic base body itself is used as a ground wire and only the signal line is passed through the inside of the base body so that it is insulated by a suitable bore of the base body. The signal line is insulated from the ground wire by a coating of an electrically insulating material applied to the base body, before the signal line is introduced into the bore. The two ends of the signal line are provided with connecting contacts, which preferably can be screwed at least partially into the base body and are mounted in such a way that they are insulated from the base body. To allow contacting of the ground wire, which is formed by the base body itself, the front end and the rear end of the base body are provided with coating-free blind bores.

Abstract: A sabot projectile with a subcaliber projectile body and a sabot, which includes a propulsion element that acts on the rear end of the projectile body and a segmented, essentially cylindrical metal guide cage, which is located at the front end of the propulsion element. The guide cage has a central opening that extends in the axial direction, through which the projectile body is passed. So that the sabot projectile is relatively inexpensive to manufacture, has a low weight, and ensures good detachment of the sabot from the projectile body after discharge, the guide cage is a hollow cylinder, on whose inside wall preferably several radial transverse ribs are arranged, which are spaced some distance apart and extend both in the direction of the longitudinal axis of the sabot and in the direction of the projectile body.

Abstract: Methods and compositions relating to Alzheimer's disease are provided. Specifically, proteins that are differentially expressed in the Alzheimer's disease state relative to their expression in the normal state are provided. Proteins associated with Alzheimer's disease are identified and described. Methods of diagnosis of Alzheimer's disease using the differentially expressed proteins are also provided, as are methods for the identification and therapeutic use of compounds for the prevention and treatment of Alzheimer's disease.

Abstract: A method of reducing or inhibiting kinase activity of FLT3 in a cell or a subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to FLT3 using a ompound of the present invention: or a solvate, hydrate, tautomer or pharmaceutically acceptable salt thereof. The present invention is further directed to methods for treating conditions such as cancers and other cell proliferative disorders.

Abstract: The invention is directed to aminopyrimidine compounds of Formula I: where R3, B, Z, r and R1 are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of FLT3 and/or c-kit and/or TrkB, the use of such compounds to reduce or inhibit kinase activity of FLT3 and/or c-kit and/or TrkB in a cell or a subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to FLT3 and/or c-kit and/or TrkB. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.

Abstract: The invention is directed to aminoquinoline and aminoquinazoline compounds of Formula I: where R1, R2, R3, B, Z, Q, p, q and X are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of FLT3 and/or TrkB, the use of such compounds to reduce or inhibit kinase activity of FLT3 and/or TrkB in a cell or a subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to FLT3 and/or TrkB. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.

Abstract: The invention is directed to a method of inhibiting FLT3 tyrosine kinase activity or expression or reducing FLT3 kinase activity or expression in a cell or a subject comprising the administration of a farnesyl transferase inhibitor and a FLT3 kinase inhibitor selected from alkylquinoline and alkylquinazoline compounds of Formula I?: where R1, R2, R3, Z, G, Q and X are as defined herein. Included within the present invention is both prophylactic and therapeutic methods for treating a subject at risk of (or susceptible to) developing a cell proliferative disorder or a disorder related to FLT3.

Abstract: The invention is directed to a method of inhibiting FLT3 tyrosine kinase activity or expression or reducing FLT3 kinase activity or expression in a cell or a subject comprising the administration of a farnesyl transferase inhibitor and a FLT3 kinase inhibitor selected from compounds of Formula I?: Included within the present invention is both prophylactic and therapeutic methods for treating a subject at risk of (or susceptible to) developing a cell proliferative disorder or a disorder related to FLT3.

Abstract: The invention is directed to aminopyrimidine compounds of Formula I: where R3, B, Z, Q, p, q and R1 are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of FLT3 and/or c-kit and/or TrkB, the use of such compounds to reduce or inhibit kinase activity of FLT3 and/or c-kit and/or TrkB in a cell or a subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to FLT3 and/or c-kit and/or TrkB. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.

Abstract: The invention is directed to a method of inhibiting FLT3 tyrosine kinase activity or expression or reducing FLT3 kinase activity or expression in a cell or a subject comprising the administration of a farnesyl transferase inhibitor and a FLT3 kinase inhibitor selected from aminopyrimidine compounds of Formula I?: where R3, B, Z, Q, p, q and R1 are as defined herein. Included within the present invention is both prophylactic and therapeutic methods for treating a subject at risk of (or susceptible to) developing a cell proliferative disorder or a disorder related to FLT3.

Abstract: The invention is directed to alkylquinoline and alkylquinazoline compounds of Formula I: wherein R1, R2, R3, B, Z, G, Q and X are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of FLT3 and/or c-kit and/or TrkB, the use of such compounds to reduce or inhibit kinase activity of FLT3 and/or c-kit and/or TrkB in a cell or a subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to FLT3 and/or c-kit and/or TrkB. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.